Table 2.
Primary outcome analyses of association between use of sodium glucose cotransporter 2 (SGLT2) inhibitors compared with glucagon-like peptide 1 (GLP1) receptor agonists and risk of serious adverse events
| Adverse event | SGLT2 inhibitors (n=17 213) | GLP1 receptor agonists (n=17 213) | Hazard ratio (95% CI) | Absolute risk difference (95% CI) | |||
|---|---|---|---|---|---|---|---|
| No of events | No of events per 1000 patient years | No of events | No of events per 1000 patient years | ||||
| Lower limb amputation | 40 | 2.7 | 22 | 1.1 | 2.32 (1.37 to 3.91) | 1.5 (0.4 to 3.3) | |
| Bone fracture | 228 | 15.4 | 263 | 13.9 | 1.11 (0.93 to 1.33) | 1.5 (−1.0 to 4.6) | |
| Diabetic ketoacidosis | 19 | 1.3 | 11 | 0.6 | 2.14 (1.01 to 4.52) | 0.7 (0.0 to 2.0) | |
| Acute kidney injury | 34 | 2.3 | 62 | 3.2 | 0.69 (0.45 to 1.05) | −1.0 (−1.8 to 0.2) | |
| Serious urinary tract infection | 80 | 5.4 | 114 | 6.0 | 0.89 (0.67 to 1.19) | −0.7 (−2.0 to 1.1) | |
| Venous thromboembolism | 63 | 4.2 | 79 | 4.1 | 0.99 (0.71 to 1.38) | 0.0 (−1.2 to 1.6) | |
| Acute pancreatitis | 20 | 1.3 | 23 | 1.2 | 1.16 (0.64 to 2.12) | 0.2 (−0.4 to 1.3) | |